CA3145363A1 - Vaccin contre le virus de la tumeur mammaire - Google Patents
Vaccin contre le virus de la tumeur mammaire Download PDFInfo
- Publication number
- CA3145363A1 CA3145363A1 CA3145363A CA3145363A CA3145363A1 CA 3145363 A1 CA3145363 A1 CA 3145363A1 CA 3145363 A CA3145363 A CA 3145363A CA 3145363 A CA3145363 A CA 3145363A CA 3145363 A1 CA3145363 A1 CA 3145363A1
- Authority
- CA
- Canada
- Prior art keywords
- mtv
- vaccine
- protein
- derived
- additional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 77
- 241000700605 Viruses Species 0.000 title description 42
- 206010006187 Breast cancer Diseases 0.000 title description 21
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 69
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 66
- 230000007704 transition Effects 0.000 claims abstract description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 15
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 14
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 11
- 229920001184 polypeptide Polymers 0.000 claims abstract description 8
- 239000000427 antigen Substances 0.000 claims description 45
- 108091007433 antigens Proteins 0.000 claims description 45
- 102000036639 antigens Human genes 0.000 claims description 45
- 241000282414 Homo sapiens Species 0.000 claims description 29
- 241000894007 species Species 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 229940031348 multivalent vaccine Drugs 0.000 claims description 11
- 229940001442 combination vaccine Drugs 0.000 claims description 8
- 101800001271 Surface protein Proteins 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 4
- 238000004873 anchoring Methods 0.000 claims description 4
- 241000975300 Concholepas concholepas Species 0.000 claims description 3
- 108010058846 Ovalbumin Proteins 0.000 claims description 3
- 108060003552 hemocyanin Proteins 0.000 claims description 3
- 229940092253 ovalbumin Drugs 0.000 claims description 3
- 201000010099 disease Diseases 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 230000003612 virological effect Effects 0.000 description 19
- 239000002245 particle Substances 0.000 description 18
- 208000026310 Breast neoplasm Diseases 0.000 description 17
- 239000002243 precursor Substances 0.000 description 15
- 102100034349 Integrase Human genes 0.000 description 12
- 108010078428 env Gene Products Proteins 0.000 description 12
- 241000282412 Homo Species 0.000 description 11
- 108010076039 Polyproteins Proteins 0.000 description 11
- 108010001267 Protein Subunits Proteins 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 101710091045 Envelope protein Proteins 0.000 description 9
- 101710202081 FAD-linked sulfhydryl oxidase Proteins 0.000 description 9
- 241000681881 Human mammary tumor virus Species 0.000 description 9
- 102100034353 Integrase Human genes 0.000 description 9
- 101710188315 Protein X Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 101710181863 Structural DNA-binding protein p10 Proteins 0.000 description 8
- 101710086987 X protein Proteins 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 102000002067 Protein Subunits Human genes 0.000 description 7
- 241001430294 unidentified retrovirus Species 0.000 description 7
- 241001493065 dsRNA viruses Species 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 231100000590 oncogenic Toxicity 0.000 description 6
- 230000002246 oncogenic effect Effects 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 101710177291 Gag polyprotein Proteins 0.000 description 5
- 241000701806 Human papillomavirus Species 0.000 description 5
- 101710125418 Major capsid protein Proteins 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 230000036952 cancer formation Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 108010089520 pol Gene Products Proteins 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 241000282465 Canis Species 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 241000450599 DNA viruses Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000004779 membrane envelope Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229940031626 subunit vaccine Drugs 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 241000714266 Bovine leukemia virus Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241001213909 Human endogenous retroviruses Species 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102000011931 Nucleoproteins Human genes 0.000 description 3
- 108010061100 Nucleoproteins Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 108091036078 conserved sequence Proteins 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229940124590 live attenuated vaccine Drugs 0.000 description 3
- 229940023012 live-attenuated vaccine Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010078762 Protein Precursors Proteins 0.000 description 2
- 102000014961 Protein Precursors Human genes 0.000 description 2
- 102100029796 Protein S100-A10 Human genes 0.000 description 2
- 101710110950 Protein S100-A10 Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940031346 monovalent vaccine Drugs 0.000 description 2
- 229940031937 polysaccharide vaccine Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 101710111216 Activated RNA polymerase II transcriptional coactivator p15 Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 206010073753 Fear of injection Diseases 0.000 description 1
- 101710101517 Gluconate operon transcriptional repressor Proteins 0.000 description 1
- 241000226709 Hesperocyparis arizonica Species 0.000 description 1
- 101100351324 Homo sapiens PDPN gene Proteins 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699658 Mus musculus domesticus Species 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 102100037265 Podoplanin Human genes 0.000 description 1
- 101710124413 Portal protein Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710156990 Protein S100-A9 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710142293 Protein p10 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920013625 Synpol Polymers 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 108010065667 Viral Matrix Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003443 anti-oncogenic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007748 combinatorial effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- -1 p 11 Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940031572 toxoid vaccine Drugs 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/12011—Betaretrovirus, e.g. mouse mammary tumour virus
- C12N2740/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/12011—Betaretrovirus, e.g. mouse mammary tumour virus
- C12N2740/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne un vaccin contenant une protéine de transition de virus de tumeur mammaire (MTV). Une autre version de l'invention est un vaccin comprenant des polypeptides de MTV couplés à une protéine porteuse. Le MTV peut être traité par l'utilisation d'un vaccin contre le MTV comprenant une protéine de transition de MTV; et l'administration dudit vaccin.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/040361 WO2021002855A1 (fr) | 2019-07-02 | 2019-07-02 | Vaccin contre le virus de la tumeur mammaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3145363A1 true CA3145363A1 (fr) | 2021-01-07 |
Family
ID=74101223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3145363A Pending CA3145363A1 (fr) | 2019-07-02 | 2019-07-02 | Vaccin contre le virus de la tumeur mammaire |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA3145363A1 (fr) |
| WO (1) | WO2021002855A1 (fr) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1067964A4 (fr) * | 1998-04-08 | 2005-05-25 | Internat Bioimmune Systems Inc | Compositions immunomodulatoires d'antigenes mmtv et leurs techniques d'application |
| ATE473758T1 (de) * | 2006-04-13 | 2010-07-15 | Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh | Her-2/neu multipeptidimpfstoff |
| US9962436B2 (en) * | 2012-07-26 | 2018-05-08 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Multimeric fusion protein vaccine and immunotherapeutic |
| US9561291B2 (en) * | 2013-03-15 | 2017-02-07 | Imre Kovesdi | Methods of targeting T-cells to tumors |
-
2019
- 2019-07-02 WO PCT/US2019/040361 patent/WO2021002855A1/fr not_active Ceased
- 2019-07-02 CA CA3145363A patent/CA3145363A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021002855A1 (fr) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7700116B2 (en) | Method of inducing an immune response in a host by administering immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) particles devoid of CD55 and CD59 in the viral membrane | |
| TWI620574B (zh) | 口蹄疫合成胜肽緊急疫苗 | |
| AU2017276249A1 (en) | Synthetic peptide-based marker vaccine and diagnostic system for effective control of Porcine Reproductive and Respiratory Syndrome (PRRS) | |
| US12029783B2 (en) | Mammary tumor virus vaccine | |
| Kabeya et al. | An effective peptide vaccine to eliminate bovine leukaemia virus (BLV) infected cells in carrier sheep | |
| Katsura et al. | Novel bovine viral diarrhea virus (BVDV) virus-like particle vaccine candidates presenting the E2 protein using the SpyTag/SpyCatcher system induce a robust neutralizing antibody response in mice | |
| US20050196411A1 (en) | Immunogenic HIV compositions and related methods | |
| US12016844B2 (en) | Mammary tumor virus suppression | |
| CA3145363A1 (fr) | Vaccin contre le virus de la tumeur mammaire | |
| KR20120131725A (ko) | 고병원성 조류인플루엔자 ａ ｈ５ｎ１ 바이러스 유사입자 및 이를 이용한 가금용 백신 | |
| Heidarnejad et al. | Investigation of Immunostimulatory Effects of IFN‐γ Cytokine and CD40 Ligand Costimulatory Molecule for Development of HIV‐1 Therapeutic Vaccine Candidate | |
| WO2021003421A1 (fr) | Suppression du virus de tumeur mammaire | |
| AU759220B2 (en) | Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV | |
| CN101134781A (zh) | 携带被插入到乙肝核心抗原蛋白或其片段内的炭疽保护性抗原表位的重组融合蛋白及其用途 | |
| US9181306B2 (en) | Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine | |
| Olagoke | Development of a vaccine to protect koalas against koala retrovirus | |
| US20240335522A1 (en) | Multivalent pan-influenza vaccine | |
| CA2548483A1 (fr) | Induction d'anticorps neutralisants antiviraux chez les hommes et les animaux | |
| RU2475264C2 (ru) | Вакцина против вич/спид | |
| Freitas et al. | Classical swine fever: Humoral neutralizing antibody induced by a live attenuated vaccine | |
| US20230285542A1 (en) | Coronavirus Vaccine | |
| Oxford | A year in the life of epidemic influenza virus | |
| Patila et al. | Immune responses of goats against foot-and-mouth disease quadrivalent vaccine: comparison of double oil emulsion and aluminium hydroxide gel vaccines in eliciting immunity | |
| WO1994002171A9 (fr) | Methode prophylactique et therapeutique de lutte contre les infections retrovirales | |
| WO1994002171A1 (fr) | Methode prophylactique et therapeutique de lutte contre les infections retrovirales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211223 |
|
| EEER | Examination request |
Effective date: 20211223 |
|
| EEER | Examination request |
Effective date: 20211223 |
|
| EEER | Examination request |
Effective date: 20211223 |
|
| EEER | Examination request |
Effective date: 20211223 |
|
| EEER | Examination request |
Effective date: 20211223 |